Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

CRMD

CorMedix Inc

Last Close
May 17 • 04:00PM ET
5.12
Dollar change
-0.08
Percentage change
-1.54 		%
Held by: VTI IWM VXF IWO VTWO IWC IWN VTWG RYLD IWV
IndexRUT P/E- EPS (ttm)-0.93 Insider Own1.84% Shs Outstand54.94M Perf Week-0.97%
Market Cap281.40M Forward P/E- EPS next Y-0.05 Insider Trans2.08% Shs Float53.95M Perf Month-5.54%
Income-50.24M PEG- EPS next Q-0.25 Inst Own31.21% Short Float18.27% Perf Quarter54.68%
Sales0.00M P/S- EPS this Y23.08% Inst Trans-8.73% Short Ratio15.19 Perf Half Y53.75%
Book/sh1.06 P/B4.85 EPS next Y93.21% ROA-78.96% Short Interest9.86M Perf Year17.03%
Cash/sh1.07 P/C4.80 EPS next 5Y- ROE-89.76% 52W Range2.57 - 7.00 Perf YTD36.17%
Dividend Est.- P/FCF- EPS past 5Y9.58% ROI-85.89% 52W High-26.86% Beta1.73
Dividend TTM- Quick Ratio6.41 Sales past 5Y-47.11% Gross Margin-596.38% 52W Low99.22% ATR (14)0.32
Dividend Ex-Date- Current Ratio6.65 EPS Y/Y TTM-17.13% Oper. Margin0.00% RSI (14)47.05 Volatility3.82% 6.16%
Employees82 Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price13.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-4.96% Payout- Rel Volume0.73 Prev Close5.20
Sales Surprise- EPS Surprise9.71% Sales Q/Q- EarningsMay 09 BMO Avg Volume648.70K Price5.12
SMA20-5.36% SMA506.49% SMA20032.17% Trades Volume475,538 Change-1.54%
Date Action Analyst Rating Change Price Target Change
Aug-10-23Initiated RBC Capital Mkts Outperform $6
Feb-17-21Initiated Needham Buy $31
Sep-29-20Initiated JMP Securities Mkt Outperform $22
Sep-21-20Initiated Truist Buy $20
Dec-18-19Initiated B. Riley FBR Buy $48
Mar-26-19Reiterated H.C. Wainwright Buy $3 → $15
Dec-06-18Initiated ROTH Capital Buy $6
Sep-25-17Reiterated H.C. Wainwright Buy $3 → $4
Aug-10-17Reiterated Rodman & Renshaw Buy $5 → $3
May-05-17Reiterated Rodman & Renshaw Buy $6 → $5
Show Previous Ratings
May-13-24 11:08AM
CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript
(Insider Monkey)
May-10-24 08:30AM
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
May-09-24 07:30AM
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
(GlobeNewswire) -5.17%
May-06-24 08:30AM
CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024
(GlobeNewswire)
May-02-24 09:55AM
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
(Zacks)
08:30AM Loading…
Apr-19-24 08:30AM
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
(GlobeNewswire)
Apr-15-24 08:30AM
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath (Taurolidine and Heparin)
(GlobeNewswire) -7.88%
Apr-11-24 09:55AM
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
(Zacks) +21.02%
08:30AM
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
(GlobeNewswire)
Apr-08-24 08:30AM
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
(GlobeNewswire)
Mar-27-24 08:30AM
CorMedix Inc. to Present at the Needham Annual Healthcare Conference
(GlobeNewswire)
Mar-12-24 08:51AM
Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities for DefenCath
(GuruFocus.com)
07:30AM
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-06-24 08:30AM
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
(GlobeNewswire)
Jan-30-24 08:30AM
CorMedix Inc. Announces Commercial and Reimbursement Updates
(GlobeNewswire) -6.27%
08:30AM Loading…
Jan-08-24 08:30AM
CorMedix Inc. Announces Commercial and Operational Updates
(GlobeNewswire) +6.49%
Dec-15-23 08:30AM
CorMedix Inc. Announces Appointment of Chief Legal Officer
(GlobeNewswire)
Dec-04-23 08:30AM
CorMedix Inc. Announces Partnership With The Leapfrog Group
(GlobeNewswire) +6.27%
Nov-15-23 12:57PM
CorMedix Inc. Announces FDA Approval of DefenCath to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
(GlobeNewswire) +6.39%
Nov-14-23 06:03PM
Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities in Q3 2023
(GuruFocus.com)
04:05PM
CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Nov-02-23 08:30AM
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
(GlobeNewswire)
Oct-11-23 08:30AM
CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
(GlobeNewswire)
Sep-26-23 08:30AM
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
(GlobeNewswire)
Sep-08-23 08:30AM
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
(GlobeNewswire)
Sep-06-23 08:30AM
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
(GlobeNewswire)
Aug-30-23 08:00AM
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
(GlobeNewswire)
Aug-10-23 10:12AM
Penn downgraded, Roblox upgraded: Wall Street's top analyst calls
(The Fly)
Aug-08-23 07:30AM
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
(GlobeNewswire) +7.94%
Jul-26-23 08:30AM
CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
(GlobeNewswire)
10:00AM Loading…
Jul-11-23 10:00AM
2 Strong Buy Penny Stocks With Massive 300% Upside Potential Or More
(TipRanks)
Jun-28-23 10:57PM
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
(GlobeNewswire)
04:07PM
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
(GlobeNewswire)
Jun-21-23 08:30AM
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
(GlobeNewswire) +5.65%
Jun-15-23 08:30AM
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
(GlobeNewswire) -5.14%
May-30-23 08:30AM
Cormedix Inc. To Present At The Jefferies Healthcare Conference
(GlobeNewswire)
May-16-23 07:00AM
CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
(GlobeNewswire) -13.40%
May-15-23 04:05PM
CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
May-08-23 08:30AM
CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023
(GlobeNewswire) +6.06%
May-03-23 08:30AM
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
May-01-23 08:30AM
CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
(GlobeNewswire)
Apr-26-23 08:30AM
CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates
(GlobeNewswire) -8.97%
Apr-17-23 08:30AM
Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors
(GlobeNewswire)
Mar-30-23 07:30AM
CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
(GlobeNewswire) +13.11%
Mar-21-23 08:30AM
Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023
(GlobeNewswire)
Mar-02-23 04:05PM
CorMedix Inc. Announces Regulatory and Manufacturing Updates
(GlobeNewswire)
Jan-17-23 08:30AM
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
(GlobeNewswire)
Dec-06-22 08:30AM
Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections
(GlobeNewswire) -9.59%
Nov-12-22 07:44AM
CorMedix Third Quarter 2022 Earnings: US$0.17 loss per share (vs US$0.23 loss in 3Q 2021)
(Simply Wall St.)
Nov-10-22 07:30AM
CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire) +9.19%
Nov-07-22 08:30AM
CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
(GlobeNewswire)
Nov-02-22 08:30AM
CorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10
(GlobeNewswire)
Oct-20-22 08:30AM
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference
(GlobeNewswire)
Sep-07-22 08:30AM
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
(GlobeNewswire) +5.33%
Aug-11-22 07:30AM
CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update
(GlobeNewswire) +10.06%
Aug-09-22 07:01AM
CorMedix Slapped With Second FDA Rejection For DefenCath
(Benzinga) -57.45%
Aug-08-22 04:05PM
CorMedix Inc. Announces Regulatory and Manufacturing Updates
(GlobeNewswire) +5.47%
Aug-01-22 08:30AM
CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11
(GlobeNewswire)
Jul-11-22 06:32AM
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
(Simply Wall St.) -6.94%
Jun-08-22 08:30AM
CorMedix to Participate at the JMP Securities Life Sciences Conference
(GlobeNewswire)
May-12-22 04:01PM
CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire)
08:30AM
CorMedix Inc. Announces Leadership Updates and Operational Changes
(GlobeNewswire)
May-03-22 08:30AM
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
(GlobeNewswire)
Apr-07-22 08:30AM
CorMedix Inc. Announces Scientific Advisory Board to Support Commercialization and Pipeline Development
(GlobeNewswire)
Apr-04-22 08:30AM
CorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Mar-29-22 04:01PM
CorMedix Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-28-22 08:30AM
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
(GlobeNewswire) -6.60%
Mar-22-22 08:30AM
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
(GlobeNewswire)
Mar-17-22 08:30AM
CorMedix Inc. Announces the Appointment of Chief Executive Officer
(GlobeNewswire)
Mar-10-22 10:55AM
2 Strong Buy Penny Stocks With Over 300% Upside Potential
(TipRanks) +7.21%
Feb-28-22 12:42PM
CorMedix Refiles DefenCath US Application For Catheter-Related Bloodstream Infections
(Benzinga) +21.39%
08:30AM
Cormedix Inc. Announces Resubmission of New Drug Application for DefenCath
(GlobeNewswire)
Feb-01-22 05:41AM
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.)
Jan-04-22 08:00AM
CorMedix to Participate in Upcoming January Conferences
(GlobeNewswire)
Nov-09-21 04:05PM
CorMedix Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
(GlobeNewswire)
Nov-02-21 09:00PM
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Live Ventures, CorMedix, Emergent BioSolutions, and Generac on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
(GlobeNewswire)
08:30AM
CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9
(GlobeNewswire)
Oct-28-21 03:05PM
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
(Zacks)
Oct-20-21 08:30AM
CorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI
(GlobeNewswire)
Oct-04-21 04:01PM
CorMedix Inc. Announces Executive Leadership Changes
(GlobeNewswire)
Sep-30-21 08:00AM
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
(PR Newswire)
Sep-20-21 12:45PM
LAWSUITS FILED AGAINST CRMD, ATVI and YALA - Jakubowitz Law Pursues Shareholders Claims
(ACCESSWIRE)
11:40AM
SHAREHOLDER ALERT: CRMD SLQT SPPI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
(ACCESSWIRE)
11:00AM
Last Few Hours for Shareholders to Actively Participate in CorMedix Inc. (CRMD) Class Action - Bronstein, Gewirtz & Grossman, LLC
(ACCESSWIRE)
11:00AM
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(ACCESSWIRE)
10:10AM
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COIN, CRMD and HNST
(ACCESSWIRE)
09:36AM
CRMD Final Deadline Today: Rosen, A Leading Investor Rights Law Firm, Encourages CorMedix Inc. Investors with Losses to Secure Counsel Before Important September 20 Deadline in Securities Class Action - CRMD
(Newsfile)
05:50AM
CLASS ACTION UPDATE for CRMD, SAVA and HNST: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
(ACCESSWIRE)
Sep-19-21 09:15PM
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(ACCESSWIRE)
01:15PM
CRMD FINAL DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CorMedix Inc. Investors with Losses to Secure Counsel Before Important September 20 Deadline in Securities Class Action CRMD
(GlobeNewswire)
10:21AM
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CRMD, ITRM and PHG
(ACCESSWIRE)
Sep-17-21 07:26PM
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against CorMedix Inc. and Encourages Investors to Contact the Firm
(Business Wire)
05:04PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 20, 2021 - CRMD
(Newsfile)
03:22PM
CRMD Final Deadline Alert: Rosen, Skilled Investor Counsel, Encourages CorMedix Inc. Investors with Losses to Secure Counsel Before Important September 20 Deadline in Securities Class Action - CRMD
(Newsfile)
01:30PM
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CRMD, KPLT and HNST
(ACCESSWIRE)
01:00PM
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CorMedix Inc. (CRMD)
(GlobeNewswire)
11:30AM
SHAREHOLDER ALERT: CRMD ZY WDH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
(ACCESSWIRE)
11:20AM
CRMD INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CorMedix Inc.
(GlobeNewswire)
10:00AM
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CRMD, SAM and WDH
(ACCESSWIRE)
10:00AM
CRMD Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CorMedix Inc. Shareholders Class Action and Lead Plaintiff Deadline: September 20, 2021
(Business Wire)
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Todisco JosephChief Executive OfficerMar 13 '24Buy3.7413,56150,718352,839Mar 14 08:45 AM
DUNTON ALAN WDirectorDec 15 '23Buy3.303,0009,90015,250Dec 18 04:47 PM
DUNTON ALAN WDirectorDec 14 '23Buy3.453,00010,35012,250Dec 18 04:47 PM
Mistry ErinChief Commercial OfficerNov 17 '23Buy4.001,0004,0004,900Nov 21 04:00 PM
Lefkowitz Steven WDirectorNov 16 '23Option Exercise2.2515,00033,75075,498Nov 17 04:50 PM
Todisco JosephChief Executive OfficerSep 08 '23Buy3.7110,00037,100219,726Sep 08 04:21 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

PTN

Palatin Technologies Inc.

Last Close
May 17 • 04:00PM ET
2.00
Dollar change
-0.04
Percentage change
-1.96 		%
PTN Palatin Technologies Inc. daily Stock Chart
Index- P/E- EPS (ttm)-2.49 Insider Own4.31% Shs Outstand16.14M Perf Week-12.66%
Market Cap32.28M Forward P/E- EPS next Y-1.13 Insider Trans-1.54% Shs Float15.44M Perf Month5.82%
Income-32.88M PEG- EPS next Q-0.48 Inst Own7.61% Short Float8.56% Perf Quarter-33.77%
Sales5.90M P/S5.47 EPS this Y15.76% Inst Trans9.70% Short Ratio2.23 Perf Half Y0.50%
Book/sh0.10 P/B20.44 EPS next Y47.03% ROA-177.67% Short Interest1.32M Perf Year-18.03%
Cash/sh0.62 P/C3.22 EPS next 5Y- ROE-588.69% 52W Range1.43 - 5.65 Perf YTD-49.75%
Dividend Est.- P/FCF- EPS past 5Y- ROI-1785.97% 52W High-64.60% Beta0.97
Dividend TTM- Quick Ratio1.20 Sales past 5Y147.86% Gross Margin84.87% 52W Low39.86% ATR (14)0.21
Dividend Ex-Date- Current Ratio1.20 EPS Y/Y TTM15.70% Oper. Margin-555.24% RSI (14)48.40 Volatility10.15% 8.90%
Employees34 Debt/Eq0.45 Sales Y/Y TTM52.80% Profit Margin-557.14% Recom1.00 Target Price8.67
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q14.56% Payout- Rel Volume0.17 Prev Close2.04
Sales Surprise-100.00% EPS Surprise-18.65% Sales Q/Q-100.00% EarningsMay 15 BMO Avg Volume591.64K Price2.00
SMA200.05% SMA508.35% SMA200-15.35% Trades Volume98,031 Change-1.96%
Date Action Analyst Rating Change Price Target Change
Jun-05-15Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15Reiterated ROTH Capital Buy $6 → $4
May-23-12Initiated Noble Financial Buy
Jan-23-07Initiated Next Generation Buy $5
May-16-24 03:05AM
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
01:46AM
Q3 2024 Palatin Technologies Inc Earnings Call
(Thomson Reuters StreetEvents)
May-15-24 07:30AM
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
(PR Newswire) -14.11%
May-09-24 07:30AM
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
(PR Newswire) +14.63%
May-02-24 07:30AM
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
(PR Newswire) +9.63%
07:30AM Loading…
Apr-30-24 07:30AM
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
(PR Newswire)
Apr-14-24 03:00PM
10 Micro-Cap Healthcare Stocks Insiders Are Buying
(Insider Monkey)
Apr-09-24 08:59AM
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
(Zacks)
Apr-08-24 12:02PM
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
(Benzinga) +14.77%
07:30AM
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
(PR Newswire)
Feb-28-24 07:30AM
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
(PR Newswire) -38.29%
Feb-16-24 10:00AM
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript
(Insider Monkey)
12:55AM
Q2 2024 Palatin Technologies Inc Earnings Call
(Thomson Reuters StreetEvents)
Feb-15-24 07:30AM
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
(PR Newswire) -23.91%
Feb-09-24 07:30AM
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
(PR Newswire) +5.72%
07:30AM Loading…
Feb-05-24 07:30AM
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
(PR Newswire) +7.67%
Feb-01-24 04:00PM
Palatin Announces Closing of $10 Million Registered Direct Offering
(PR Newswire) -14.25%
Jan-30-24 08:00AM
Palatin Announces $10 Million Registered Direct Offering
(PR Newswire) -10.62%
Jan-11-24 01:38PM
3 Penny Stocks to Buy to Unlock 2,500% Upside Potential
(InvestorPlace)
Jan-08-24 10:33AM
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
(PR Newswire) +12.73%
Jan-03-24 08:00AM
Cosette Pharmaceuticals Acquires Vyleesi (Bremelanotide Injection) from Palatin Technologies Inc.
(Business Wire) -10.62%
Dec-23-23 05:00PM
Analysts Say 3 Stocks Have a Combined Upside of 3000%
(InvestorPlace)
Dec-20-23 07:30AM
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
(PR Newswire)
Dec-18-23 04:15PM
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
(PR Newswire) -8.30%
Nov-15-23 03:01PM
Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript
(Insider Monkey)
03:29AM
Q1 2024 Palatin Technologies Inc Earnings Call
(Thomson Reuters StreetEvents)
Nov-14-23 07:30AM
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
(PR Newswire)
Nov-09-23 07:30AM
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
(PR Newswire)
Oct-24-23 04:50PM
Palatin Announces Closing of $5 Million Registered Direct Offering
(PR Newswire)
Oct-23-23 07:30AM
Palatin Announces $5 Million Registered Direct Offering
(PR Newswire) -13.75%
08:45AM Loading…
Oct-19-23 08:45AM
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
(PR Newswire) +22.54%
07:30AM
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
(PR Newswire)
Oct-18-23 07:30AM
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
(PR Newswire)
Oct-16-23 07:30AM
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
(PR Newswire)
Oct-13-23 04:15PM
Palatin Receives Notice of Non-Compliance from NYSE American
(PR Newswire)
Oct-03-23 08:35AM
Palatin Technologies, Inc. (AMEX:PTN) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Sep-29-23 01:34AM
Q4 2023 Palatin Technologies Inc Earnings Call
(Thomson Reuters StreetEvents)
Sep-28-23 07:30AM
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
(PR Newswire) -9.09%
Sep-22-23 04:00PM
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
(PR Newswire) -5.66%
Sep-07-23 04:00PM
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(PR Newswire)
07:30AM
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
(PR Newswire)
Aug-10-23 07:30AM
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
(PR Newswire) -5.50%
Aug-08-23 07:30AM
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
(PR Newswire) +8.20%
Aug-07-23 07:30AM
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth for Vyleesi®
(PR Newswire) +23.86%
Aug-04-23 07:30AM
Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
(PR Newswire)
Jul-11-23 07:30AM
Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results
(PR Newswire)
May-30-23 07:30AM
Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
(PR Newswire)
May-17-23 01:39PM
Palatin Technologies, Inc. (AMEX:PTN) Q3 2023 Earnings Call Transcript
(Insider Monkey) -5.43%
01:33AM
Q3 2023 Palatin Technologies Inc Earnings Call
(Thomson Reuters StreetEvents)
May-16-23 08:45AM
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
07:30AM
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
(PR Newswire)
May-15-23 09:05AM
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
(Zacks) +17.19%
May-11-23 05:25PM
TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:15PM
Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
(PR Newswire)
May-09-23 05:45PM
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
07:30AM
Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
(PR Newswire)
May-08-23 04:04PM
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar
(PR Newswire) +7.62%
May-01-23 04:00PM
Palatin Technologies to Host Key Opinion Leader Webinar
(PR Newswire)
Apr-27-23 07:30AM
Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference
(PR Newswire)
Apr-25-23 07:30AM
Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma
(PR Newswire) -8.20%
Apr-19-23 07:30AM
Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results
(PR Newswire)
Apr-18-23 07:30AM
Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences
(PR Newswire)
Mar-02-23 07:30AM
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease
(PR Newswire) -9.17%
Feb-28-23 07:30AM
Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
(PR Newswire) +18.50%
Feb-15-23 07:30AM
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
(PR Newswire)
Feb-10-23 07:30AM
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
(PR Newswire)
Jan-26-23 05:45PM
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
Jan-19-23 07:30AM
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
(PR Newswire)
Jan-18-23 07:30AM
Palatin Receives $4.7 Million of Non-Dilutive Funding
(PR Newswire)
Jan-10-23 07:30AM
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
(PR Newswire) +16.53%
Jan-05-23 07:30AM
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
(PR Newswire)
Nov-14-22 08:55AM
Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates
(Zacks) -7.71%
07:30AM
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
(PR Newswire)
Nov-10-22 08:55AM
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
Nov-09-22 06:45PM
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
05:16PM
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
(PR Newswire)
Nov-08-22 07:25PM
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
(Zacks) -5.96%
Nov-07-22 05:15PM
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates
(Zacks) -5.24%
Oct-31-22 09:30AM
Palatin Announces $10 Million Registered Direct Offering
(PR Newswire)
Oct-27-22 07:05AM
Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates
(Zacks)
Oct-24-22 05:32PM
Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
(PR Newswire) +8.05%
Oct-20-22 07:30AM
First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial
(PR Newswire)
Oct-17-22 07:30AM
Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)
(PR Newswire)
Oct-13-22 07:30AM
Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
(PR Newswire)
Sep-29-22 03:45PM
Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
(PR Newswire)
01:31PM
Palatin to Participate in Ladenburg Thalmann Healthcare Conference
(PR Newswire)
Sep-22-22 11:00AM
Edited Transcript of PTN.A earnings conference call or presentation 22-Sep-22 3:00pm GMT
(Thomson Reuters StreetEvents) -12.36%
09:22AM
Palatin Technologies Shares Drop After Wider Than Expected Quarterly Loss
(Benzinga)
07:30AM
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
(PR Newswire)
Sep-19-22 04:15PM
Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022
(PR Newswire)
Sep-08-22 07:30AM
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
(PR Newswire) +26.20%
Sep-02-22 10:28AM
3 Penny Stocks That Could 10X by 2023
(InvestorPlace) +6.98%
Aug-19-22 07:30AM
Palatin Announces Intent to Effect Reverse Stock Split
(PR Newswire) -15.65%
Aug-16-22 07:30AM
Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease
(PR Newswire) -6.55%
Jul-26-22 07:30AM
Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter
(PR Newswire)
Jul-13-22 10:53AM
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
(Zacks) -5.10%
May-17-22 08:45AM
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
07:30AM
Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
(PR Newswire)
May-16-22 07:15AM
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) +5.38%
May-12-22 08:15AM
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEVEER ROBERT K JRDirectorApr 11 '24Buy2.126,00012,70340,845Apr 11 04:45 PM
DEVEER ROBERT K JRDirectorMar 06 '24Sale2.0011,70023,43434,845Mar 07 05:02 PM
WILLS STEPHEN TExecutive VP and CFO/COODec 06 '23Sale2.514,99812,563327,522Dec 08 05:30 PM
DUNTON ALAN WDirectorDec 04 '23Sale2.4820049645,074Dec 06 05:02 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.